DOCSLIB.ORG

Vienna Biocenter 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vienna Biocenter 2007 RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY VIENNA BIOCENTER 2007 CONTENTS Introduction 2 Of Blood and Stones 4 The Scent of a Man 6 The IMP and Its Surroundings 8 Your Career at the IMP 9 RESEARCH GROUPS Hartmut Beug 10 Meinrad Busslinger 12 Tim Clausen 14 Carrie Cowan 16 Barry Dickson 18 Frank Eisenhaber 20 Christine Hartmann 22 Thomas Jenuwein 24 Ludger Klein 26 Thomas Marlovits 28 Jan-Michael Peters 30 Simon Rumpel 32 Peggy Stolt-Bergner 34 Erwin Wagner 36 Stefan Westermann 38 Anton Wutz 40 RESEARCH SUPPORT Katrin Heinze 42 Vienna Drosophila RNAi Center (VDRC) 44 SCIENTIFIC SERVICES Biooptics Department 46 Electron Microscopy 47 Bioinformatics 48 Protein Chemistry Facility 49 Histology Department 50 Animal House 51 Mouse Service 51 Service Department 52 Scientific Advisory Board 53 Publications 54 Awards 57 Seminar Speakers 58 Spotlight on 2007 61 Administration and Other Services 62 Impressum 64 Where We Are 64 2 | IMP REPORT 2007 BARRY DICKSON HARALD ISEMANN Managing Director/Science Director/Finance and Administration Birthdays are always fun, particularly the round numbers. And with past. For now, let’s just take a quick review of the highlights the IMP entering its 20th year, there really is plenty to celebrate. of the past year. It must have seemed crazy 20 years ago when Boehringer Ingelheim and Genentech decided to create a new biomedical After some frustrating technical delays, we are all relieved research institute in the run-down part of a city that – despite a that the mice have now finally moved into the spacious new strong intellectual tradition – was not exactly a vibrant center IMP-IMBA mouse house. An undertaking of this scale is never of scientific innovation at the time. But with hindsight, this was easy, and this one was certainly not without its complications. an inspired decision. But now, thanks to the heroic efforts of Andreas Bichl and his team, as well as Alex Chlup and the technical department, the In Vienna, the IMP has had an impact that it might not have had mice are all now happily breeding in their new home. Thanks also elsewhere. It has served as a role model for the neighbouring to Erwin Wagner, who has skillfully guided the whole operation institutes of the University of Vienna and the Medical University, from the very beginning. now restructured as the Max F. Perutz Laboratories (MFPL), as well as two new institutes of the Austrian Academy of Sciences Another significant achievement of the past year was the – IMBA and GMI. And the biotech company Intercell, founded as establishment of the Vienna Drosophila RNAi Center (VDRC). a spin-off of the IMP and the University, has grown to become The VDRC maintains the genome-wide Drosophila RNAi library one of Europe’s most successful biotech companies. The Campus and distributes lines world-wide through an online ordering Vienna Biocenter that has sprung up around the IMP is now system. The VDRC also supports the many RNAi screens being one of the most dynamic and innovative life science centers conducted within IMBA and the IMP. Generous funding from the in Europe. City of Vienna and the Ministry of Science covers much of the bill, the rest by user fees. Krystyna Keleman, Reinhard Klug, and There are many people to thank for this; too many to list here. their team have done a terrific job in setting up the VDRC. Suffice it to say that this would not have been possible without the vision and generous support of Boehringer Ingelheim, The Electron Microscopy facility, set up last year and headed by the strong leadership of Max Birnstiel and Kim Nasmyth, the Günter Resch, has just added a new 300kV Polara transmission pioneering spirit of the “founding fathers” who staked their EM primarily for cryo-electron tomography to their 100kV scientific careers on a small renovated loudspeaker factory Morgani transmission EM. in the 3rd district, and the efforts and spirit of a great many scientists and support staff. The City of Vienna and the Austrian As every year, we have had to say a few sad good-byes, but also Federal Government have also played a pivotal role. And it is welcome new members into the IMP family. After eight years remarkable how Vienna itself has also changed over these 20 at the IMP, Frank Eisenhaber left us to take up an exciting new years, becoming one of the most enjoyable, affordable, and challenge as Head of the Bioinformatics Institute at Biopolis, cosmopolitan cities in Europe. Singapore. Frank established the computational biology and much of the IT infrastructure at the IMP, and contributed to several We’re looking forward to the 20th birthday celebrations in key discoveries. Almost immediately after arriving at the IMP, May, 2008. We will host a two-day symposium at the Hofburg Frank had the insight that Thomas Jenuwein’s Suv3-9 proteins at which all speakers will be former or current members of the were likely to be histone methyl transferases – a prediction that IMP, or chairs of our Scientific Advisory Board. The impressive Steven Rea and Thomas famously confirmed. list of speakers is itself a wonderful testament to the IMP’s success in launching so many outstanding scientific careers. Ludger Klein is also leaving at the end of the year to take up a There will be much more time next May for reflecting on the professorship at the LMU in Munich. Ludger will be remembered INTRODUCTION IMP REPORT 2007 | 3 not only for his elegant use of transgenic mice to define the With his active participation in everything from the PhD program cellular mechanisms of T-cell tolerance, but also for his remarkable and seminar series to lively lunchtime discussions, Graham is ability to give seminars in immunology that even a Drosophila already a familiar figure to everyone at the Campus. One exciting geneticist could understand! new initiative now being hatched is to establish a campus-wide facility for massively parallel DNA sequencing. With a Solexa 1G Diane Turner also left us this year, after almost 20 years of and a 454 sequencer, we’ll soon be able to enter a whole new cheerful and selfless work in support of all IMP scientisits. era of DNA sequencing. We have been very fortunate to recruit Manuela Jung to join Chris Robinson in the Scientific Secretariat. In all, it’s been yet another exciting year at the IMP, and we also have much to look forward to in the new year. Many thanks to all Another new recruit is our second IMP fellow. David Keays has of the IMP scientists and the support staff at IMP and IMBA for signed on and will join us in the new year. During his PhD studies their fantastic efforts, as well as to Boehringer Ingelheim and our with Jonathan Flint in Oxford, Dave studied a mouse model of other sponsors for their generous support. We were particularly mental retardation. He plans to continue some of the mouse delighted that Christian Boehringer, the new chairman of the work, but also take on an ambitious new project – investigating shareholder´s committee, visited the IMP in August. With all the the molecular basis of magnetoreception. We look forward to changes on Campus in the past few years, the IMP in her 20s is welcoming Dave to the IMP next year. very different than she was in her childhood and adolescence. The 20s are good years – no less exciting, and a good age for Finally, a wonderful boost for the Campus this year has been great discoveries. Happy Birthday, IMP! the arrival of Graham Warren as Scientific Director of the MFPL. INTRODUCTION 4 | IMP REPORT 2007 OF BLOOD AND STONES One of the central tenets of developmental biology is that recent results from César Cobaleda in Meinrad Busslinger’s lab development – like evolution – is irreversible. In other words, (Nature 449, 473-477). differentiated cells cannot be made to de-differentiate, except Since 1990, work in Meinrad’s group has been largely focussed on maybe under extreme in vitro conditions. Enabling differenti- the Pax5 (paired box protein 5) gene, one of the nine Pax genes ated cells to enter a different cell lineage under physiological known to be present in the mammalian genome. The genes conditions is one of the primary aims of regenerative medicine are named after their conserved “paired” domain, which binds but experiments towards this goal have been likened to the with varying affinity to a set of distinct and loosely conserved alchemists’ quest for the philosopher’s stone, a mythical rock sequences of DNA. The Pax genes are transcription factors made from the transmutation of gold, silver and mercury that and Pax5 is the only one expressed within the mammalian can heal all injuries and sicknesses of the human body and hematopoietic system. It was first identified as a DNA-binding transmutate any base metal into gold and silver. protein that interacts with the promoters of immunoglobulin The search for the philosopher’s stone seems to have been genes and was thus thought to be responsible for confining discontinued, except perhaps in certain highly specialized expression of these genes to particular cells. Subsequent work circles, but regenerative medicine is still receiving an enormous has shown that Pax5 has a much wider part to play in control- amount of attention. And it has been boosted considerably by ling the development of B cells from hematopoietic stem cells. Without Pax5, development of B cells is arrested at an early stage: progenitor B cells (pro-B cells) are produced but do not differentiate further. As long ago as 2001, Markus Horcher in Meinrad’s group was able to show that inactivation of Pax5 in mature B cells caused loss of these cells, although the mechanism was unclear (Immunity 14, 779-790).
Load more

Recommended publications
  • NCI RAS Initiative Update
    Ras Initiative Update Frank McCormick and Levi Garraway DEPARTMENT OF HEALTH AND HUMAN SERVICES • National Institutes of Health • National Cancer Institute The Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute RAS Initiative Accomplishments: Evaluating Ras dependency 2 SiREN assay for Ras dependency SiREN assay for Ras dependency 70% KD siEGFP 0-10% KD 50% KD 100% KD SiREN assay for Ras dependency RAS Initiative Accomplishments: Biophysical and structural analysis 7 Ras proteins 1 -166 167-185,6 Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Palmitoyl Farnesyl Fully processed KRAS4b A. Gorfe, U-Texas Houston Engineering baculovirus for improved production of processed KRAS • recombineering used to insert FNTA/FNTB genes into the baculovirus genome • eliminated issues with coinfection of multiple viruses • maltose-binding protein (MBP) fusion for greater yield and solubility • Trichoplusia ni (Hi5) insect cells for increased yield Carissa Grose, Dom Esposito, Bill Gillette Processed KRAS4b characterization • Extensive protein characterization – Purified to homogeneity; yield >7mg/L – Intact mass – Predominantly monomeric – Secondary structure equivalent to non-processed KRAS4b KRAS4b- FME – Lower thermal stability Intact mass analysis Analytical ultracentrifugation Secondary structure by CD 2.14 S 25.7 kDa 10 Bill Gillette, Zhaojing Meng, Shelley Perkins,
    [Show full text]
  • Miriam Molina Arcas
    CV Miriam Molina Arcas Miriam Molina Arcas Principal Laboratory Research Scientist The Francis Crick Institute 1 Midland Road, NW1 1AT London +442037963313 miriam.molina@crick.ac.uk EDUCATION 1999-2005 PhD in Biomedicine, University of Barcelona, Spain Role of equilibrative nucleoside transporters in the sensitivity to antineoplasic drugs. Supervisors: Prof. Marçal Pastor-Anglada and Dr. F. Javier Casado 1994-1999 BSc Biochemistry, University of Barcelona, Spain RESEARCH AND PROFESSIONAL EXPERIENCE June 2016- present Senior Laboratory Research Scientist, Oncogene Biology Laboratory, The Francis Crick Institute. Prof. Julian Downward. Studied combination approaches that improve the efficacy of KRAS inhibitors and reduce resistance mechanisms. March 2015- May 2016 Postdoctoral Fellow, Lung Cancer Team, Institute of Cancer Research. Prof. Julian Downward. Designed and optimized a whole-genome shRNA screen to identify synthetic lethal interactions with MEK and IGF1R inhibitors. Sep 2008- Feb 2015 Postdoctoral Fellow, Signal Transduction Laboratory, Cancer Research UK- London Research Institute. Prof. Julian Downward Using RNA interfering and drug screens, identified new therapeutic strategies to treat tumours harbouring KRAS mutations 2006- Aug 2008 Postdoctoral Fellow, University of Barcelona, Spain Prof. Marçal Pastor-Anglada Studied the role of membrane transporters in nucleoside-derived drug response in cancer and HIV. TEACHING AND MENTORING EXPERIENCE 2018-2021 Honorary Research Associate in the School of Life & Medical Sciences, University College London, part of the Certificate in Core Teaching Practices. 2007-2008 Part-time lecturer of Biochemistry and Molecular Biology (University of Barcelona). 180h of theory and practical lessons. 2003-2005 Teaching assistant of Biochemistry and Molecular Biology (University of Barcelona). 60h of practical lessons. September 2019 Co-supervisor of MSc Experimental Pharmacology and Therapeutics Research of Pablo Romero Clavijo at the University College London.
    [Show full text]
  • (Sozial)Leben in Graz & Oberschützen
    (SOZIAL)LEBEN IN GRAZ & OBERSCHÜTZEN 1 Wissenswertes über ÖSTERREICH Du möchtest in Österreich studieren? Wir haben dir hier ein paar wichtige Fakten zusammengestellt, damit du dich schnell zurechtfindest! FACTS ÜBER ÖSTERREICH Hauptstadt: Einwohner_innenzahl: Wien ca. 8,8 Mio. Größe: Währung: 83.858 km² Euro (€ 1 = 100 Cent) Bundesländer: Nachbarländer: Burgenland, Kärnten, Niederösterreich, Deutschland, Italien, Liechtenstein, Schweiz, Oberösterreich, Salzburg, Steiermark, Tirol, Slowakei, Slowenien, Tschechien, Ungarn Vorarlberg, Wien Klima: Zeitzone: Gemäßigtes Klima: milde Sommer mit Mitteleuropäische Zeitzone (MEZ), UTC + 1, Hitzeperioden (bis zu +30 °C), kalte und nasse 2x/Jahr (Ende März/Ende Oktober): Winter mit Schnee (bis zu -15 °C) Zeitumstellung Berühmte österreichische Künstler_innen: Fauna und Flora: Wolfgang Amadeus Mozart, Johann Strauss, Keine Kängurus , dafür ist aber die Elfriede Jelinek, Joseph Haydn, Franz Schubert, mitteleuropäische Tierwelt vorzufinden: z.B. Franz Liszt, Anton Bruckner, Egon Schiele, Gustav Rehe, Hirsche, Hasen, Fasanen, Füchse, Dachse, Klimt, Oskar Kokoschka, Gustav Mahler, Peter Marder, Rebhühner u.v.m. Handke, Thomas Bernhard, Helmut Qualtinger, Außerdem gibt es viele Laubwälder (Eichen, u.v.m. Buchen) bzw. Mischwälder (Buchen, Fichten) in höheren Regionen Fichten, Lärchen und Zirben. Traditionelle österreichische Küche: Sportliche Aktivitäten: z.B. Tafelspitz, Wiener Schnitzel, Steirisches z.B. Wintersport: Skifahren, Langlaufen, Backhendl, Gulasch, Sachertorte, Eislaufen, Sommersport: Radfahren,
    [Show full text]
  • Unveiling New Disease, Pathway, and Gene Associations Via Multi-Scale Neural Networks
    Unveiling new disease, pathway, and gene associations via multi-scale neural networks Thomas Gaudelet 1, No¨elMalod-Dognin 2, Jon S´anchez-Valle 2, Vera Pancaldi 2,3,4, Alfonso Valencia 2,5,6 and NataˇsaPrˇzulj 2,5,∗ 1 Department of Computer Science, University College London, London, WC1E 6BT 2 Department of Life Sciences, Barcelona Supercomputing Center (BSC), Barcelona, 08034 Spain 3 Centre de Recherches en Canc´erologiede Toulouse (CRCT), UMR1037 Inserm, ERL5294 CNRS, 31037 Toulouse, France 4 University Paul Sabatier III, Toulouse, France 5 ICREA, Pg. Llu´ısCompanys 23, 08010 Barcelona, Spain 6 Coordination Node. Spanish National Bioinformatics Institute, ELIXIR-Spain (INB, ELIXIR-ES), Spain ∗ natasha@bsc.es. Abstract Diseases involve complex modifications to the cellular machinery. The gene expression profile of the affected cells contains characteristic patterns linked to a disease. Hence, new biological knowledge about a disease can be extracted from these profiles, improving our ability to diagnose and assess disease risks. This knowledge can be used for drug re-purposing, or by physicians to evaluate a patient's condition and co-morbidity risk. Here, we consider differential gene expressions obtained by microarray technology for patients diagnosed with various diseases. Based on these data and cellular multi-scale organization, we aim at uncovering disease{disease, disease{gene and disease{pathway associations. We propose a neural network with structure based on the multi- scale organization of proteins in a cell into biological pathways. We show that this model is able to correctly predict the diagnosis for the majority of patients. Through the analysis of the trained model, we predict disease{ disease, disease{pathway, and disease{gene associations and validate the predictions by comparisons to known interactions and literature search, proposing putative explanations for the predictions.
    [Show full text]
  • Fellows Opted out of the Mentoring Programme As of 21 July 2020 1 of 3 Professor Chris Abell FRS Fmedsci Professor Philip Jones
    Fellows opted out of the Mentoring programme as of 21 July 2020 Professor Chris Abell FRS FMedSci Professor Philip Jones FMedSci Professor David Adams FMedSci Professor Roger Jones FMedSci Professor Judith Allen FRSE FMedSci Professor Kamlesh Khunti FMedSci Professor Thomas Kirkwood CBE Professor Desmond Archer OBE FMedSci FMedSci Professor Louise Arseneault FMedSci Professor Robb Krumlauf FMedSci Professor Charalambos Kyriacou Professor Michael Arthur FMedSci FMedSci Professor Deborah Ashby OBE FMedSci Sir Peter Lachmann FRS FMedSci Professor Dame Frances Ashcroft DBE Professor Leon Lagnado FMedSci FRS FMedSci Professor Anthony Barrett FRS FMedSci Professor Ajit Lalvani FMedSci Professor Gillian Bates FRS FMedSci Professor Deborah Lawlor CBE FMedSci Professor Facundo Batista FMedSci Professor Joy Lawn FMedSci Professor Stephan Beck FMedSci Professor Susan Lea FMedSci Professor Jill Belch OBE FMedSci Professor Sir Robert Lechler PMedSci Professor Sir John Bell GBE FRS Dr Melanie Lee CBE FMedSci HonFREng FMedSci Professor Wendy Bickmore FRS FRSE Professor Andrew Lees FMedSci FMedSci Professor Sir Adrian Bird CBE FRS FRSE Professor Stafford Lightman FRS FMedSci FMedSci Professor Ewan Birney CBE FRS Professor Janet Lord FMedSci FMedSci Professor Dorothy Bishop FRS FBA Professor Thomas MacDonald FMedSci FMedSci Professor Rona MacKie CBE FRSE Professor Jane Blazeby FMedSci Sir Stephen Bloom FRS FMedSci Professor Giovanna Mallucci FMedSci Sir Tom Blundell FRS FMedSci Dr Fiona Marshall FMedSci Professor Dame Theresa Marteau DBE Professor Peter
    [Show full text]
  • Drugging the Undruggable: Advances on RAS Targeting in Cancer
    G C A T T A C G G C A T genes Review Drugging the Undruggable: Advances on RAS Targeting in Cancer Miriam Molina-Arcas 1,*, Amit Samani 1,2,* and Julian Downward 1,3 1 Oncogene Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK; julian.downward@crick.ac.uk 2 Department of Medical Oncology, Imperial College Healthcare NHS Trust, London W2 1NY, UK 3 Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK * Correspondence: miriam.molina@crick.ac.uk (M.M.-A.); amit.samani@nhs.net (A.S.) Abstract: Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective therapies despite decades of research. Recently, characterisation of the biochemical properties of KRAS-G12C along with discovery of its ‘switch-II pocket’ have allowed development of effective mutant-specific inhibitors. Currently seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we discuss historical efforts to target RAS directly and approaches to target RAS effector signalling, including combinations that overcome limitations of single-agent targeting. We also review pre-clinical and clinical evidence for the efficacy of KRAS-G12C inhibitor monotherapy followed by an illustration of combination therapies designed to overcome primary resistance and extend durability of response. Finally, we briefly discuss novel approaches to targeting non-G12C mutant isoforms.
    [Show full text]
  • Second RAS Initiative Symposium Sponsored by the National Cancer Institute Advanced Technology Research Facility, Frederick, MD December 6-8, 2017
    The Second RAS Initiative Symposium Sponsored by the National Cancer Institute Advanced Technology Research Facility, Frederick, MD December 6-8, 2017 December 6 8:00 am – 8:15 am Welcome from the NCI Director Norman Sharpless 8:15 am – 9:00 am Keynote Frank McCormick (RAS Initiative, University of California, San Francisco) 9:00 am – 9:30 am Organoids as Model Systems for Tumorigenesis Calvin Kuo (Stanford University) 9:30 am – 9:50 am Break 9:50 am – 12:10 pm Activated RAS and Oncogenesis - Chair: Jeff Settleman Douglas Lowy (National Cancer Institute) Christopher Counter (Duke University) Matthew Vander Heiden (Massachusetts Institute of Technology) Marie Evangelista (Genentech) Aaron Hobbs (Der Lab, University of North Carolina, Chapel Hill) 12:10 pm – 1:10 pm Lunch on your own 1:10 pm – 3:15 pm Poster Session #1 3:15 pm – 4:15 pm RAS Multimers at the Membrane - Chair: John Hancock Yao-Cheng Li (Wahl Lab, Salk Institute) Margie Sutton (Bast Lab, MD Anderson) Chiara Ambrogio (Jänne Lab, Dana Farber Cancer Institute) 4:15 pm – 5:30 pm RAS Membrane Modeling and Dynamics - Chair: Dwight Nissley Roland Winter (Technische Universität Dortmund) Fred Streitz (Lawrence Livermore National Laboratory) Chris Neale (Garcia Lab, Los Alamos National Laboratory) Walkersville Social Hall 79 West Frederick Street, Walkersville 6:15 – 7:00 pm Hors d’oeuvres, cash bar 7:00 pm Dinner December 7 8:00 am – 10:00 am Tumor Dynamics - Chair: Rosalie Sears Dafna Bar-Sagi (New York University) David Tuveson (Cold Spring Harbor Laboratory) Channing Der (University
    [Show full text]
  • Zusammenstellung Österreichischer Museen Mit Volkskundlichem Charakter 39-67 © Bundesministerium F
    ZOBODAT - www.zobodat.at Zoologisch-Botanische Datenbank/Zoological-Botanical Database Digitale Literatur/Digital Literature Zeitschrift/Journal: Österreichs Museen stellen sich vor Jahr/Year: 1980 Band/Volume: 13 Autor(en)/Author(s): Gottschall Klaus Artikel/Article: Zusammenstellung österreichischer Museen mit volkskundlichem Charakter 39-67 © Bundesministerium f. Wissenschaft und Forschung; download unter www.zobodat.at Dr. Klaus Gottschall ZUSAMMENSTELLUNG ÖSTERREICHISCHER MUSEEN MIT VOLKSKUNDLICHEM CHARAKTER Die Liste der hier aufgeführten Museen beansprucht keine Vollständig­ keit. Die angeführten Daten wurden dankenswerter Weise von den ver­ schiedenen Landesmuseen zur Verfügung gestellt. Im wesentlichen spie­ gelt diese Liste den Stand Mai 1980. Lediglich vom Lande Niederöster­ reich konnten Daten nur ex 1973/1974 vermittelt werden. Auch das Land Kärnten mußte zeitbedingt umfangsmäßig Einschränkungen vornehmen. Ähnliches gilt für das Land bzw. die Stadt Wien; hier mußte eine Be­ schränkung insoferne vorgenommen werden, als nur die überregionalen bzw. Großmuseen aufgenommen wurden. Die zahlreichen, wichtigen Be­ zirksmuseen konnten nicht mehr erfaßt werden. Literaturhinweise: Rotraut ACKER-SUTTER: Heimatmuseen im Lande Salzburg. Selbstverlag des Salzburger Bildungswerkes, Salzburg 1980, 152 S. Gudrun B.-KLOSTER (Hg.); Handbuch der Museen. Deutschland BRD, DDR, Ö sterreich, Schweiz. Bd. 2: DDR, Österreich, Schweiz, Register. V er­ lag D okum entation, M ünchen-Pullach und Berlin 1971, XVI S., S. 643 bis 1300. österreichische FREMDENVERKEHRSWERBUNG (Hg.): Museen und Kunstdenkmäler in Österreich. Wien o. J., 88 S. Paul GNUVA: Museen in Europa. Wichtige und originelle Sammlungen. Kunst, Natur, Technik, Folklore, Hobby. RV Reise- und Verkehrsverlag GmbH., Berlin 1977, 296 S. Franz C. LIPP, Heidelinde DIMT: Schloßmuseum Linz. Führer durch die Sammlungen. Oberösterreichischer Landesverlag, Linz 1978, 192 S. Wolfgang MILAN (Bearb.): Museen und Sammlungen in Österreich.
    [Show full text]
  • Landesmuseum Joanneum Graz Jahresbericht
    ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at LANDESMUSEUM JOANNEUM GRAZ JAHRESBERICHT 1982 ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at 2 Abteilung für Mineralogie LandesmuseumJoanneum Raub© rgçisee 10 A-8010 Graz, AUSTRIA ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at LANDESMUSEUM JOANNEUM GRAZ, JAHRESBERICHT 1982 ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at LANDESMUSEUM JOANNEUM GRAZ JAHRESBERICHT 1982 NEUE FOLGE 12 - GRAZ 1983 ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at Nach den Berichten der Abteilungen redigiert von Eugen B r eg a n t und Dr. Detlef E rn et Graz 1983 Herausgegeben von der Direktion des Steiermärkischen Landesmuseums Joanneum, Raubergasse 10/1, A-8010 G raz Direktor: Dr. Friedrich W aidacher Gesamtherstellung: Buch- und Offsetdruckerei Styria, Judenburg Gesetzt aus Sabon — Berthold ©Digitalisierung Biologiezentrum Linz; download www.zobodat.at Inhalt Kuratorium 7 Bautätigkeit und Einrichtung 11 Sonderausstellungen 13 Veranstaltungen 19 Besuchsstatistik 1982 25 Verkäufliche Veröffentlichungen 27 Verkäufliche Diapositive und Bildpostkarten 33 Berichte Direktion 35 Referat für Jugendbetreuung 39 Abteilung für Geologie, Paläontologie und Bergbau 44 Abteilung für Mineralogie 51 Abteilung für Botanik 60 Abteilung für Zoologie 70 Abteilung für Vor- und Frühgeschichte und Münzensammlung 82 Abteilung für Kunstgewerbe 89 Landeszeughaus 95 Alte Galerie 101 Neue Galerie 105 Steirisches Volkskundemuseum 111 Außenstelle Stainz 116 Jagdmuseum 120 Abteilung Schloß Eggenberg 126 Landschaftsmuseum Schloß Trautenfels 134 Bild- und Tonarchiv 137 Beiträge K. R. Lorenz: Das geistige Erbe Erzherzog Johanns. Überlegungen zum Erzherzog-Johann-Gedenkjahr 145 F. Ebner: Erfahrungen mit der Wanderausstellung „Fossilien in der Steiermark — 500 Millionen Jahre Erdgeschichte“ 149 Z.
    [Show full text]
  • № Wca № Castles Prefix Name of Castle Oe-00001 Oe-30001
    № WCA № CASTLES PREFIX NAME OF CASTLE LOCATION INFORMATION OE-00001 OE-30001 OE3 BURGRUINE AGGSTEIN SCHONBUHEL-AGGSBACH, AGGSTEIN 48° 18' 52" N 15° 25' 18" O OE-00002 OE-20002 OE2 BURGRUINE WEYER BRAMBERG AM WILDKOGEL 47° 15' 38,8" N 12° 19' 4,7" O OE-00003 OE-40003 OE4 BURG BERNSTEIN BERNSTEIN, SCHLOSSWEG 1 47° 24' 23,5" N 16° 15' 7,1" O OE-00004 OE-40004 OE4 BURG FORCHTENSTEIN FORCHTENSTEIN, MELINDA-ESTERHAZY-PLATZ 1 47° 42' 34" N 16° 19' 51" O OE-00005 OE-40005 OE4 BURG GUSSING GUSSING, BATTHYANY-STRASSE 10 47° 3' 24,5" N 16° 19' 22,5" O OE-00006 OE-40006 OE4 BURGRUINE LANDSEE MARKT SANKT MARTIN, LANDSEE 47° 33' 50" N 16° 20' 54" O OE-00007 OE-40007 OE4 BURG LOCKENHAUS LOCKENHAUS, GUNSERSTRASSE 5 47° 24' 14,5" N 16° 25' 28,5" O OE-00008 OE-40008 OE4 BURG SCHLAINING STADTSCHLAINING 47° 19' 20" N 16° 16' 49" O OE-00009 OE-80009 OE8 BURGRUINE AICHELBURG ST. STEFAN IM GAILTAL, NIESELACH 46° 36' 38,6" N 13° 30' 45,6" O OE-00010 OE-80010 OE8 KLOSTERRUINE ARNOLDSTEIN ARNOLDSTEIN, KLOSTERWEG 3 46° 32' 55" N 13° 42' 34" O OE-00011 OE-80011 OE8 BURG DIETRICHSTEIN FELDKIRCHEN, DIETRICHSTEIN 46° 43' 34" N 14° 7' 45" O OE-00012 OE-80012 OE8 BURG FALKENSTEIN OBERVELLACH-PFAFFENBERG 46° 55' 20,4" N 13° 14' 24,6" E OE-00014 OE-80014 OE8 BURGRUINE FEDERAUN VILLACH, OBERFEDERAUN 46° 34' 12,6" N 13° 48' 34,5" E OE-00015 OE-80015 OE8 BURGRUINE FELDSBERG LURNFELD, ZUR FELDSBERG 46° 50' 28" N 13° 23' 42" E OE-00016 OE-80016 OE8 BURG FINKENSTEIN FINKENSTEIN, ALTFINKENSTEIN 13 46° 37' 47,7" N 13° 54' 11,1" E OE-00017 OE-80017 OE8 BURGRUINE FLASCHBERG OBERDRAUBURG,
    [Show full text]
  • Combining Three Antibodies Nullifies Feedback-Mediated Resistance to Erlotinib in Lung Cancer
    RESEARCH ARTICLE CANCER Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer Maicol Mancini,1 Nadège Gaborit,1 Moshit Lindzen,1 Tomer Meir Salame,2 Massimiliano Dall’Ora,1 Michal Sevilla-Sharon,1 Ali Abdul-Hai,1,3 Julian Downward,4,5 Yosef Yarden1* Despite initial responses to targeted kinase inhibitors, lung cancer patients presenting with primary epidermal growth factor receptor (EGFR) mutations acquire resistance, often due to a second-site mutation (T790M). However, clinical trials found no survival benefits in patients treated with a monoclonal antibody (mAb) to EGFR that should block activation of the mutated receptor and thus bypass resistance to molecules that target the catalytic or ATP-binding site. Using cell lines with the T790M mutation, we discovered that pro- longed exposure to mAbs against only the EGFR triggered network rewiring by (i) stimulating the extra- Downloaded from cellular signal–regulated kinase (ERK) pathway; (ii) inducing the transcription of HER2 (human epidermal growth factor receptor 2) and HER3, which encode other members of the EGFR family, and the gene encoding HGF, which is the ligand for the receptor tyrosine kinase MET; and (iii) stimulating the interaction between MET and HER3, which promoted MET activity. Supplementing the EGFR-specific mAb with those targeting HER2 and HER3 suppressed these compensatory feedback loops in cultured lung cancer cells. The triple mAb com- bination targeting all three receptors prevented the activation of ERK, accelerated the degradation of the re- ceptors, inhibited the proliferation of tumor cells but not of normal cells, and markedly reduced the growth of http://stke.sciencemag.org/ tumors in mice xenografted with cells that were resistant to combined treatment with erlotinib and the single function-blocking EGFR mAb.
    [Show full text]
  • Life Changing Science
    LIFE CHANGING SCIENCE The Francis Crick Institute Annual Review 2017/18 AN INSTITUTE FOR DISCOVERY Our commitment to excellence, our emphasis on multidisciplinary research, our focus on young and emerging talent and our novel ways of partnership working are some of the factors that set the Crick apart. Front cover Vaccinia virus infection (green) disrupts a layer of epithelial cells (red/blue). Courtesy of Michael Way, Group Leader at the Crick. INTRODUCTION 2 Who we are Our year at a glance 2 Introduction by Paul Nurse 4 The Francis Crick Institute is a biomedical Progress against our strategy 6 discovery institute dedicated to understanding the RESEARCH HIGHLIGHTS 10 Cancer-causing mutation fundamental biology underlying health and disease. suppresses immune system 11 Our work is helping to build an understanding of Predicting lung cancer’s return 12 New understanding of human why disease develops and to translate discoveries embryo development 14 Chemical attraction could improve into new ways to prevent, diagnose and treat cancer immunotherapy 16 illnesses such as cancer, heart disease, stroke, Genes linked to malaria parasites’ persistence 17 infections and neurodegenerative diseases. Architecture of our ‘second brain’ 18 Cause of infertility side-stepped in mice 19 Mechanism for spinal cord development discovered 20 A new layer of complexity in embryo development 21 Two DNAs wedded with this ring 22 Unravelling how DNA gets copied 23 Telomerase’s dark side discovered 24 REVIEW OF THE YEAR 26 New group leaders arrive 27 Joined-up thinking 30 Focusing on the molecules of life 32 CryoEM at the Crick 34 Bringing academia and industry closer together 36 The people making research happen 38 Patterns in art and science 40 Rewarding research 42 Appointments 43 Supporting new discoveries 44 Our vision What’s inside Our vision is to be a world- We bring together outstanding scientists Science feature 32 leading multidisciplinary from all disciplines and carry out research Sophisticated microscopy is being biomedical research institute.
    [Show full text]